2024
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial
Piltin M, Norwood P, Ladores V, Mukhtar R, Sauder C, Golshan M, Tchou J, Rao R, Lee M, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman L, Boughey J. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7420-7428. PMID: 38980586, DOI: 10.1245/s10434-024-15708-9.Peer-Reviewed Original ResearchPathological complete responseEvent-free survivalPatients treated with neoadjuvant chemotherapyNeoadjuvant chemotherapyDistant recurrenceLocoregional recurrenceOncological outcomesClinical trialsRate of locoregional recurrenceResponse to neoadjuvant chemotherapyInternal mammary lymphadenopathyModern neoadjuvant chemotherapyHigh tumor gradeMethodsWe evaluated patientsBreast cancer stageAxillary surgeryComplete responseMedian followTumor gradePretreatment imagingLarger tumorsPrognostic indicatorI-SPY2Comparing patientsCancer stage
2011
P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017).
De L, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017). Cancer Research 2011, 71: p2-08-02-p2-08-02. DOI: 10.1158/0008-5472.sabcs11-p2-08-02.Peer-Reviewed Original ResearchRadiographic complete responseNeoadjuvant systemic therapyInvasive breast cancerSystemic therapyBreast cancerHR-/HER2Systemic treatmentTumor gradePathologic complete response rateTumor phenotypeBasis of estrogenComplete response rateOperable breast cancerMulticenter retrospective studyNeoadjuvant systemic treatmentMorbidity of surgeryHER2 receptor statusPrediction of pCRBreast cancer subtypesMagnetic resonance imagingHR-HER2IHC phenotypeChemotherapy regimenNeoadjuvant chemotherapyTN subtype